NASDAQ$LENZ
LENZ Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
LENZ Therapeutics reported Q3 2025 revenue of $12.5M, a net loss of $16.7M, diluted EPS of $-0.59.
For Q3 2025, LENZ Therapeutics reported Revenue was $12.5M, net loss was $16.7M, diluted EPS was $-0.59. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Revenue $12.5M for Q3 2025.
- Net loss $16.7M.
- Diluted EPS $-0.59.
Headline financials
Revenue & EPS history
LENZ Therapeutics Inc · Revenue · Quarterly
$12.5M
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Collaboration, licensing, or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q3 2025
-2.8%
Avg return
Earnings day
-3.7%
Avg return
5 days after
-5.1%
Avg return
30 days after
20%
2 / 10 earnings
Positive
+5.0%
Q2 2022
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | -7.0% | — | |
| Q1 2026 | -0.8% | -27.1% | -34.5% | |
| Q3 2025 | -23.5% | -17.3% | -4.7% | |
| Q2 2025 | -2.9% | -7.4% | +22.0% | |
| Q3 2023 | -1.7% | -0.4% | -1.3% | |
| Q2 2023 | -4.5% | -4.5% | -17.4% | |
| Q1 2023 | -0.3% | -3.2% | -8.4% | |
| Q3 2022 | +1.9% | +7.1% | +1.9% | |
| Q2 2022 | +5.0% | +9.3% | -9.0% | |
| Q1 2022 | -0.9% | +13.9% | +5.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro